Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 4 | 2020 | 412 | 1.220 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 608 | 0.970 |
Why?
|
| Internship and Residency | 2 | 2018 | 313 | 0.920 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2019 | 17 | 0.720 |
Why?
|
| Medical Oncology | 2 | 2020 | 86 | 0.710 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 217 | 0.710 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.700 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.690 |
Why?
|
| Taxoids | 1 | 2020 | 59 | 0.690 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 4 | 0.690 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2019 | 9 | 0.680 |
Why?
|
| Median Nerve | 1 | 2020 | 51 | 0.680 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 18 | 0.680 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 51 | 0.670 |
Why?
|
| Communication | 1 | 2020 | 142 | 0.660 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 185 | 0.640 |
Why?
|
| Teaching | 1 | 2018 | 62 | 0.620 |
Why?
|
| Ultrasonography | 1 | 2020 | 379 | 0.580 |
Why?
|
| Internal Medicine | 1 | 2017 | 54 | 0.560 |
Why?
|
| Sulfides | 1 | 2016 | 26 | 0.560 |
Why?
|
| Caprylates | 1 | 2016 | 27 | 0.560 |
Why?
|
| Curriculum | 1 | 2017 | 213 | 0.500 |
Why?
|
| Physicians | 1 | 2017 | 158 | 0.490 |
Why?
|
| Lung | 1 | 2016 | 249 | 0.490 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 353 | 0.450 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 765 | 0.440 |
Why?
|
| Neoplasms | 2 | 2018 | 726 | 0.410 |
Why?
|
| Humans | 13 | 2020 | 32005 | 0.310 |
Why?
|
| Pilot Projects | 2 | 2020 | 545 | 0.280 |
Why?
|
| Aged | 6 | 2020 | 10301 | 0.250 |
Why?
|
| Weight Loss | 1 | 2008 | 480 | 0.230 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 638 | 0.230 |
Why?
|
| Male | 8 | 2020 | 19165 | 0.200 |
Why?
|
| Reference Standards | 1 | 2020 | 32 | 0.180 |
Why?
|
| Middle Aged | 6 | 2020 | 11817 | 0.180 |
Why?
|
| Ankle | 1 | 2020 | 29 | 0.180 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.180 |
Why?
|
| Albumins | 1 | 2020 | 45 | 0.180 |
Why?
|
| Microglia | 1 | 2020 | 57 | 0.180 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.180 |
Why?
|
| Forearm | 1 | 2020 | 43 | 0.170 |
Why?
|
| Nerve Fibers | 1 | 2020 | 37 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2020 | 75 | 0.170 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.170 |
Why?
|
| Wrist | 1 | 2020 | 48 | 0.170 |
Why?
|
| Leg | 1 | 2020 | 65 | 0.170 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 18 | 0.170 |
Why?
|
| Laryngeal Neoplasms | 1 | 2019 | 15 | 0.170 |
Why?
|
| Papillomaviridae | 1 | 2019 | 22 | 0.170 |
Why?
|
| Neural Conduction | 1 | 2020 | 91 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1428 | 0.160 |
Why?
|
| Cranial Irradiation | 1 | 2019 | 93 | 0.160 |
Why?
|
| Risk | 1 | 2019 | 321 | 0.160 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 48 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 67 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 726 | 0.160 |
Why?
|
| Female | 7 | 2020 | 19959 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 39 | 0.150 |
Why?
|
| Nicotine | 1 | 2020 | 171 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2018 | 81 | 0.150 |
Why?
|
| Energy Intake | 2 | 2008 | 128 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 183 | 0.140 |
Why?
|
| Topotecan | 1 | 2016 | 17 | 0.140 |
Why?
|
| Education, Medical | 1 | 2017 | 69 | 0.140 |
Why?
|
| Educational Measurement | 1 | 2017 | 123 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 835 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2018 | 333 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1531 | 0.130 |
Why?
|
| Adult | 5 | 2019 | 9345 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2020 | 2282 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 367 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 458 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 220 | 0.080 |
Why?
|
| United States | 1 | 2017 | 3939 | 0.080 |
Why?
|
| Agaricales | 1 | 2007 | 1 | 0.080 |
Why?
|
| Meat | 1 | 2007 | 15 | 0.080 |
Why?
|
| Baltimore | 1 | 2008 | 50 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2007 | 110 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 271 | 0.060 |
Why?
|
| Overweight | 1 | 2007 | 280 | 0.060 |
Why?
|
| Adolescent | 2 | 2008 | 3539 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3990 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 6 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 21 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 25 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2019 | 3509 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 167 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 84 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1175 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2008 | 3306 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 291 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 57 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 148 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 447 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 753 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 981 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1497 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 2484 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1817 | 0.030 |
Why?
|
| Animals | 1 | 2020 | 7541 | 0.020 |
Why?
|
| Satiety Response | 1 | 2007 | 1 | 0.020 |
Why?
|
| Thinness | 1 | 2007 | 33 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 95 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 463 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 161 | 0.020 |
Why?
|